Skip to main content

Market Overview

Recap: Synlogic Q1 Earnings


Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 9.80% year over year to ($0.46), which missed the estimate of ($0.43).

Revenue of $100,000 less by 70.41% year over year, which missed the estimate of $450,000.


Earnings guidance hasn't been issued by the company for now.

Synlogic hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 08, 2020

Webcast URL:

Recent Stock Performance

52-week high: $10.01

Company's 52-week low was at $1.35

Price action over last quarter: Up 44.65%

Company Profile

Synlogic Inc is a biopharmaceutical company focused on advancing the drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer.


Related Articles (SYBX)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at